Opioid and Opioid Tolerance Flashcards

1
Q

Agonist

A

† Strong agonist: morphine, hydromorphone, oxymorphone,

methadone, meperidine, fentanyl, levorphanol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

† Partial agonist

A

codeine, oxycodone, hydrocodone,

propoxyphrene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Antagonist

A

† Nalorphine, naloxone, naltrexone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mixed agonist-antagonist

A

† Nalbuphine,burenorphine, butophenol, pentazocine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

… Short-acting

A

† All medication released at once
† Peaks and valleys effect
† Acute or break through pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

… Long-acting examples

A

† MS Contin, Oxycontin, Kadian

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

long acting do not

A

crush you will get a bolus and overdose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

long acting remember

A

† Small amounts released over time, providing more stable
blood level
† Good for chronic pain management

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

new recommendations are calling for

A

short acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

… Clinical Indications for opioids

A

† Acute and chronic pain, Acute pulmonary edema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Route and Onset

A
† Parenteral 5-15 min
† Neuraxial 5 min
† Transdermal 16-24h
† Transmucosal (Oral and nasal) rapid-15min
† IM 60 min (erratic)
† PO 40-60min
† Intrathecal/epidural 5-15min
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Opioid MOA

A

Bind to receptors in CNS (Mu, Kappa, Delta)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

… Supraspinal (medulla and midbrain) - MOA

A

† Activation of post-synaptic neurons
† Inhibition of neurons involved in pain transmission by
increased influx of K+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Spinal MOA/Activity

A

† Activation of presynaptic receptors
† Increased Ca++ influx and decreased release of
nociceptive neurotransmitters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Absorption/Distribution/ Metabolism/Elmination

A
… Absorption
† First pass effect
… Distribution
† Lungs liver kidney spleen slow penetration of blood Lungs, liver, kidney, spleen, slow penetration of bloodbrain barrier; storage in fat, skeletal muscle
… Metabolism
… Elimination: renal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MU 1

A

… Mu1: Supraspinal analgesia, euphoria, miosis, bradycardia,

urinary retention

17
Q

MU 2

A

Mu2: Spinal analgesia, respiratory depression, decreased GI

18
Q

KAPPA

A

Kappa: Supraspinal/spinal analgesia, sedation, miosis,

diuresis, hallucinations, respiratory depression

19
Q

DELTA

A

Delta: supraspinal analgesia, respiratory depression, urinary
retention

20
Q

Opioid Other effects

A

Other Effects: constipation, biliary colic, orthostatic

hypotension

21
Q

opioid tolerance is dependent on

A

Dependent on dose, dosing frequency, duration and

consistency of use

22
Q

opioid tolerance charcitresitics

A

† Shorter duration of pain relief
† Decrease in peak analgesic effect
† Increasing amount needed to achieve relief

23
Q

opioid tolerance managment

A

† Lengthen time between doses

† Increase dose to avoid shorter dosing interval

24
Q

no more than ___ MME for acute pain

A

700

25
Q

Opioid Dependence

3 or more of the following:

A
… Drug tolerance
… Withdrawal symptoms
… Use of the drug in larger
amounts or for longer
i d th i d f
… Significant time spent
obtaining the substance or
recovering from its effects
… Foregoing of important
activities or willingness to periods than required for
medical necessity
… Repeated unsuccessful
attempts to decrease or
discontinue use
… Drug use to avoid
withdrawal
activities, or willingness to
accept severe physical,
social, or professional
negative consequences, due
to drug use
26
Q

Physical Dependence

A

Repeated opioid use leads to physical adaptation

of body to drug and physical need for opioids

27
Q

… Withdrawal symptoms experienced when off

opioids for

A

36-72 h

28
Q

duration of withdrawal

A

2 to 5 weeks

29
Q

physical dependence resutls in

A

continued use of drug despite negative consequences

30
Q

Psychological Dependence

A

Continued drug use for reasons other than tolerance
and withdrawal, such as the experience from a
drug’s pleasurable effects or to block out or to
escape from reality

31
Q

Addiction

A

Addiction is a primary, chronic, neurobiologic disease,
with genetic, psychosocial, and environmental factors
influencing its development and manifestations. It is
characterized by behaviors that include one or more
of the following: impaired control over drug use,
compulsive use, continued use despite harm, and
craving.
… American Pain Society

32
Q

Opioid Addiction

A

… Most severe form of dependence
… Patient has uncontrollable cravings for the drug
… Is willing to risk any adverse consequences to obtain
it
… Requires ever-higher doses in order to ward off
withdrawal and/or to obtain the pleasurable
narcotic high associated with the drug

33
Q

Drug interactions

A

… CNS depressants
† Sedative- hypnotics, alcohol, anesthetics, barbiturates
… GI/GU effects (constipation, urinary retention)
† Anticholinerg , ,p ics, TCAs, phenothiazines
… MAOIs (coma, HTN)
… Cimetidine enhances opioid effects
… Diuretics (orthostatic hypotension)
… Nicotine decreases effects of opioids

34
Q

Contraindications and Precautions

A
… Use in patient with
head injuries
… Pregnancy
… Impaired pulmonary
… Hypersensitivity
… Abdominal pain
… Labor and Delivery
… Impaired pulmonary … ETOH
function
… Impaired hepatic or
renal function
… ETOH
… Prostate disease
… Urinary strictures